DMAC – diamedica therapeutics inc. (US:NASDAQ)
Stock Stats
News
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch [Yahoo! Finance]
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke [Yahoo! Finance]
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Form 8-K DiaMedica Therapeutics For: Apr 05
Form EFFECT DiaMedica Therapeutics
Form ARS DiaMedica Therapeutics For: Dec 31
Form DEFA14A DiaMedica Therapeutics
Form DEF 14A DiaMedica Therapeutics For: May 22
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.